Loading...
01/10 16:38
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals significant challenges: a 17.3% revenue decline, increased customer acquisition costs, and a high leverage ratio of 3.76. Despite cost-saving measures, the market strategy and financial health sections show weak performance and guidance, with no shareholder return plans. The Q&A highlights management's cautious outlook and lack of clear guidance on key metrics. These factors suggest a negative stock price reaction over the next two weeks, especially given the uncertain consumer environment and financial leverage risks.
Revenue $39.4 million, declining 17.3% from Q1 2024; decline driven by lower case volume despite a slight increase in average revenue per case.
Adjusted EBITDA $3.8 million, down from $7.3 million in Q1 2024; margin decreased to 9.5% from 15.4% due to revenue declines.
Same-store revenue Declined approximately 24% year-over-year; consistent with expectations and Q4 trend.
Cases 3,076 cases, a decline of 17.9% year-over-year; decline attributed to a soft consumer environment and reduced marketing spend.
Average revenue per case $12,799, slightly higher than Q1 2024.
Customer acquisition cost $3,130 per case, up from $2,990 in the prior year; increase driven by lower case volumes and reduced advertising spend.
Cash flow from operations $0.9 million, down from $3.4 million in Q1 2024.
Cash $5.6 million as of March 31, 2025.
Gross debt outstanding $74.7 million; leverage ratio at 3.76 times.
New Services: Launched a pilot of skin tightening procedure in Q2 2025 to tap into more consumer demand.
Revenue Guidance: Expecting fiscal 2025 revenue in the range of $160 million to $170 million.
Lead Generation: Generated strong lead volume growth over Q1 last year by reallocating marketing dollars.
Adjusted EBITDA: Adjusted EBITDA was $3.8 million for a margin of 9.5%, down from $7.3 million and a margin of 15.4% in Q1 2024.
Cost Discipline: Disciplined cost actions delivered $1.9 million more in adjusted EBITDA versus Q4 2024.
Customer Acquisition Cost: Customer acquisition cost was $3,130 per case, up from $2,990 in the prior year quarter.
Marketing Strategy: Reallocated marketing spend to proven strategies, including search engine marketing and social media.
Sales Optimization: Invested in sales training and refined processes to improve lead conversion.
Technology Investment: Launching expanded financing options to provide customers with added flexibility.
Consumer Environment: The company is facing headwinds from a softening consumer environment, which has led to a decline in revenue and case volume.
Marketing Spend: A reduction in marketing spend in the second half of 2024 has contributed to lower case volumes, impacting revenue.
Economic Conditions: The company acknowledges the uncertain consumer spending environment and has built conservatism into its revenue guidance for fiscal 2025.
Financing Options: The percentage of patients using financing to pay for procedures has decreased to 44%, below the previous 50%, indicating potential challenges in consumer purchasing behavior.
Cost Structure: Fixed costs such as rent and nursing do not scale down with revenue fluctuations, leading to increased costs as a percentage of revenue.
Customer Acquisition Costs: Customer acquisition costs have increased to $3,130 per case, driven by lower case volumes and reduced advertising spend.
Debt Levels: The company has a gross debt of $74.7 million and a leverage ratio of 3.76 times, indicating financial leverage that may pose risks.
Regulatory Issues: The company is monitoring consumer behavior related to inflationary pressures and tariffs, which could impact discretionary spending on procedures.
Cost Discipline and Marketing Efficiency: The company is focusing on cost discipline, marketing efficiency, and operational rigor to stabilize performance and lay the foundation for long-term growth.
Sales and Marketing Strategy: The company has reallocated marketing spend to proven strategies, resulting in improved lead generation and a robust database for future conversions.
New Services Introduction: A pilot for a skin tightening procedure has been launched to tap into more consumer demand, representing a new revenue stream.
Customer Experience Enhancement: Initiatives are in development to improve the customer journey, expected to roll out in the back half of the year and into 2026.
Technology Investments: The company is launching expanded financing options and new technology enhancements to improve sales efficiency.
Revenue Guidance: Fiscal 2025 revenue is expected to be in the range of $160 million to $170 million.
Adjusted EBITDA Guidance: Adjusted EBITDA is projected to be between $16 million and $18 million for fiscal 2025.
Market Conditions: The guidance reflects current economic conditions with conservatism due to uncertain consumer spending.
Leverage Ratio: The company aims to reduce its leverage ratio to historical levels, currently at 3.76 times.
Share Repurchase Program: None
The earnings call presents a negative outlook, with reduced revenue guidance, declining financial performance, and high leverage limiting flexibility. Despite some cost-cutting measures, the revenue and EBITDA have decreased, and the company faces challenges with new services. The Q&A highlighted uncertainties in cost savings and service expansion, with management providing vague responses. Given these factors, a negative stock price movement is likely, reflecting the company's current financial struggles and market uncertainties.
The earnings call summary shows a challenging macro environment with a decline in same-store revenue and cases, despite some cost reductions and improved cash flow. The Q&A section highlights consumer hesitancy, uncertainty in revenue guidance, and lack of clear data on new initiatives like skin tightening. The leverage ratio improvement is positive, but overall, weak financial performance and guidance uncertainty suggest a negative sentiment.
The earnings call reveals significant challenges, including a 17.3% revenue decline, increased customer acquisition costs, and financial leverage concerns. Despite some cost savings and potential future improvements, the current negative consumer environment and reduced marketing spend are impacting performance. The lack of a share repurchase program and avoidance of direct answers in the Q&A further contribute to a negative sentiment. Although there are plans for cost savings and improvements, the immediate outlook remains challenging, leading to a predicted negative stock price movement.
The earnings call reveals significant challenges: a 17.3% revenue decline, increased customer acquisition costs, and a high leverage ratio of 3.76. Despite cost-saving measures, the market strategy and financial health sections show weak performance and guidance, with no shareholder return plans. The Q&A highlights management's cautious outlook and lack of clear guidance on key metrics. These factors suggest a negative stock price reaction over the next two weeks, especially given the uncertain consumer environment and financial leverage risks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
